Oil prices recently moved above $110 a barrel as conflict risks around Iran and Saudi Arabia increased, and that puts global inflation and healthcare costs back in the spotlight. For Canadian biotech stocks, that renewed focus on medical needs and treatments can draw fresh attention to drug developers with solid finances. This article highlights three Toronto listed biotech picks from our screener that combine balance sheet discipline with potential upside.
The three Canadian biotech stocks covered below are only a small sample of what screens well on balance sheet strength and pricing, and the full filter surfaced 6 more companies with equally compelling narratives that are not included in this article. If you want to identify and analyze more biotech ideas with similar traits, head straight into the Biotech Stocks screener
Bright Minds Biosciences (CNSX:DRUG)
Overview:Bright Minds Biosciences develops serotonin receptor based drug candidates like BMB-101 to address severe epilepsy and neuropsychiatric disorders.
Market Cap:CA$782 million
Bright Minds Biosciences fits the Biotech Stocks theme through its 5-HT2 focused epilepsy pipeline, early Phase 2 data, and sub $1 million revenue base. The stock presents a high-risk biotech profile, with clinical readouts and funding needs both in play. As a result, a single shift in expectations around trial progress could significantly affect returns.
With that kind of binary setup in play, it may be wise to step back, review the full 2 key rewards and 3 important warning signs (1 is major!) , and understand it before those trial headlines start driving the story.
Cronos Group (TSX:CRON)
Overview:Cronos Group cultivates and commercializes cannabinoid based cannabis products, using in house R&D to support branded flowers, vapes, oils, edibles and tinctures.
Operations:Cronos Group generates about $179 million from cannabis cultivation, manufacturing and marketing, primarily in Canada with meaningful contributions from Israel.
Market Cap:CA$1.71 billion
Cronos Group matters for this Biotech Stocks screen because its cannabinoid R&D is directly tied to what ends up in higher value branded products.
"The in house genetics program, which has produced over 150,000 seeds and screened more than 6,000 genotypes since 2018 with less than 1% reaching market, can keep feeding higher potency and higher yielding strains into GrowCo and international partners and support a mix shift toward premium SKUs that can lift gross margin and EBITDA over time."
What happens to future profitability if a single assumption about where those premium products can legally scale turns out too optimistic?
If that legal ceiling is what really matters for Cronos Group, reading the full narrative for Cronos Group shows how regulation, cash and optionality could be quietly decoupling.
Green Thumb Industries (CNSX:GTII)
Overview:Green Thumb Industries manufactures, distributes, and sells cannabinoid based medical and adult use cannabis products across the United States.
Operations:The business produces about $846 million from Retail and $681 million from Consumer Packaged Goods, almost entirely within the United States.
Market Cap:CA$1.91 billion
Green Thumb Industries brings a biotech angle to this cannabis focused screen through its cannabinoid formulations. The main point of interest for investors is how those science backed products support a large retail and consumer packaged goods footprint.
"Continued federal rescheduling progress and Green Thumb Industries' DEA registrations for medical operations create scope for lower effective tax rates and cheaper financing over time, which could lift net margins and earnings power beyond what current models assume."
Investors may also want to consider what happens to per share results if a single pressure point on its cash rich balance sheet and buyback runway moves in a more favorable direction.
If that shift is what you are watching, the full narrative for Green Thumb Industries brings together how tax, capital and product traction could be quietly accelerating.
Seeking Alternatives Before Momentum Flies
Fresh ideas move first. By the time every chart looks like a breakout, the easy entry can be gone. Scan these under the radar lists now and act early.
-
Spot rising cash generators before momentum screens catch up by combing through the 4 high quality undervalued stocks while pricing dislocations still look temporary.
-
Track capital rushing into digital assets by scanning the 20 cryptocurrency and blockchain stocks and see which business models hold up if token excitement cools.
-
Target reliable income streams while yields remain elevated by reviewing the 3 dividend fortresses before prices adjust and payouts compress.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
